BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy
NCT00017043 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2013-04-05
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have metastatic stomach cancer previously treated with chemotherapy.
Conditions
- Esophageal Cancer
- Gastric Cancer
Interventions
- DRUG
-
ixabepilone
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH - lead INDUSTRY
Principal Investigators
-
Manish A. Shah, MD · Memorial Sloan Kettering Cancer Center
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2001-02-28
- Primary Completion
- 2003-01-31
- Completion
- 2003-01-31
Countries
- United States
Study Locations
More Related Trials
-
Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction
NCT00080002 ·Status: TERMINATED ·Phase: PHASE2
-
Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
NCT00074009 ·Status: COMPLETED ·Phase: PHASE2
-
Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin
NCT00397904 ·Status: COMPLETED ·Phase: PHASE2
-
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
NCT03469557 ·Status: COMPLETED ·Phase: PHASE2
-
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
NCT03704077 ·Status: WITHDRAWN ·Phase: PHASE2
-
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
NCT04079712 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
NCT04021108 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
NCT02872116 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors
NCT02016534 ·Status: TERMINATED ·Phase: PHASE2
-
Study of FMT Combined With Nivolumab in Gastric Cancer
NCT05001360 ·Status: WITHDRAWN ·Phase: NA
-
Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT00084604 ·Status: COMPLETED ·Phase: PHASE2
-
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer
NCT00719550 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer
NCT00215644 ·Status: COMPLETED ·Phase: PHASE2
-
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
NCT03427814 ·Status: COMPLETED ·Phase: PHASE2
-
Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the Stomach
NCT00075465 ·Status: UNKNOWN ·Phase: PHASE2
-
Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
NCT04034251 ·Status: TERMINATED ·Phase: PHASE2
-
Cabozantinib and Nivolumab for Carcinoid Tumors
NCT04197310 ·Status: COMPLETED ·Phase: PHASE2
-
TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
NCT04891900 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
NCT00813072 ·Status: COMPLETED ·Phase: PHASE2
-
Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer
NCT02076594 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer
NCT01630083 ·Status: COMPLETED ·Phase: PHASE2
-
DX-8951f in Treating Patients With Metastatic Stomach Cancer
NCT00017212 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
NCT06947291 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation
NCT04308837 ·Status: RECRUITING ·Phase: PHASE2
-
Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the Esophagus
NCT00003192 ·Status: COMPLETED ·Phase: PHASE2